What is semaglutide used for?

Semaglutide is approved for two main indications: treatment of type 2 diabetes (Ozempic/Rybelsus) and chronic weight management in adults with obesity or overweight with weight-related conditions (Wegovy).

How much weight can you lose on semaglutide?

In clinical trials, participants lost an average of 15-17% of their body weight over 68 weeks with semaglutide 2.4 mg (Wegovy). Individual results vary and depend on adherence to lifestyle modifications.

Semaglutide has been extensively studied and approved by major regulatory agencies. Common side effects are primarily gastrointestinal. Serious risks exist and the medication is not suitable for everyone. Use should be supervised by a healthcare provider.

How long do you need to take semaglutide?

Obesity is considered a chronic condition, and most guidelines recommend ongoing treatment to maintain weight loss. Discontinuation typically results in weight regain. Duration should be determined with your healthcare provider.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide but at different doses and for different approved uses. Ozempic (0.5-1 mg weekly) is approved for type 2 diabetes; Wegovy (2.4 mg weekly) is approved for weight management.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Fat Loss & Metabolic•Updated 2026-02-01•6 min read

What Is Semaglutide? Benefits, Research & Safety

A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.

Share:X Post LinkedIn

Also known as:

Ozempic

Wegovy

Rybelsus

GLP-1 receptor agonist (brand-class)

AStrong human evidenceUK: Prescription-only (UK POM)WADA: Sport status unclear

UK summary: Licensed UK medicine (Ozempic for type 2 diabetes; Wegovy for chronic weight management). Prescription-only. Lawful access is through a registered UK prescriber and a regulated pharmacy. Counterfeit pens are a major UK safety issue.

Quick Facts

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is a modified analogue of human GLP-1, a hormone naturally produced in the gut in response to food intake. Semaglutide has been approved by major regulatory authorities including the FDA, EMA, and MHRA for the treatment of type 2 diabetes and, at higher doses, for chronic weight management. The peptide works by mimicking the effects of GLP-1, which plays crucial roles in glucose regulation and appetite control. By activating GLP-1 receptors, semaglutide stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety—leading to reduced food intake and weight loss. What distinguishes semaglutide from native GLP-1 is its modified structure that dramatically extends its half-life from minutes to approximately one week. This allows for once-weekly injection or once-daily oral administration, greatly improving convenience compared to earlier GLP-1 analogues. Clinical trials have demonstrated remarkable efficacy, with participants losing an average of 15-17% of body weight in obesity trials—unprecedented results for pharmacological weight loss interventions. This has led to significant interest and demand for semaglutide-based treatments. Semaglutide is available under several brand names: Ozempic (for diabetes), Wegovy (for obesity), and Rybelsus (oral formulation for diabetes).

Evidence standards summary

Semaglutide — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

AStrong human evidenceOverall grade against our evidence grading methodology.

Licensed UK medicine (Ozempic for type 2 diabetes; Wegovy for chronic weight management). Prescription-only. Lawful access is through a registered UK prescriber and a regulated pharmacy. Counterfeit pens are a major UK safety issue.

02Human evidence grade

AStrong human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: MHRA approved. Ozempic licensed for type 2 diabetes; Wegovy licensed for weight management.
EU: EMA approved for type 2 diabetes (Ozempic) and weight management (Wegovy).
Notes: Semaglutide is a fully approved prescription medication in the UK, EU, USA, and many other countries. It should only be obtained through legitimate medical channels and used under healthcare supervision.

05Approved medical uses

Wegovy — UK weight management (NICE TA875)
Ozempic — UK type 2 diabetes
Rybelsus — UK type 2 diabetes (oral)

06Unapproved / promotional claims

Cures type 2 diabetes
Safe and effective for cosmetic / non-clinical weight loss in any BMI
Reverses metabolic syndrome
Equivalent to ‘research-grade semaglutide’ from online vials

07Common internet claims

Skinny shot / weight-loss miracle
Compounded semaglutide is the same as Wegovy at half the price
Use Ozempic off-label for cosmetic weight loss
Take any GLP-1 you can get hold of during a Wegovy shortage

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Causes substantial weight loss (~15% body weight)”	A	Yes	Low	Large human RCTs (STEP programme) show mean weight loss around 15% at 68 weeks for Wegovy 2.4 mg, with individual variation.
“Reduces cardiovascular events in eligible patients”	B	Yes	Low	Cardiovascular outcomes data exist; the magnitude and applicability depend on the specific population and indication.
“Available over-the-counter online — no prescription needed”	E	No	High	Semaglutide is a UK prescription-only medicine. Online sources selling it without a prescription operate outside UK law.
“Research-only semaglutide vials are equivalent to Wegovy”	E	No	High	Grey-market 'research' product is not verifiable as genuine pharma-grade semaglutide. Identity, purity, and dosing are unverified.
“No side effects — perfectly safe”	E	No	High	Common side effects are mostly gastrointestinal. Rarer serious risks exist. Always discuss with a prescriber.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Nausea, vomiting, diarrhoea, constipation (common, dose-dependent)
Gallbladder disease — recognised class effect
Pancreatitis — recognised but uncommon
Contraindicated in pregnancy and breastfeeding
Counterfeit pen risk via unlicensed supply chains

11Drug-interaction uncertainty

Low

Drug-interaction picture documented in the prescribing information.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Prescription-only (UK POM)

MHRA approved. Ozempic licensed for type 2 diabetes; Wegovy licensed for weight management.

Read the full UK legal guide → Semaglutide and UK law

14EU legal position

EMA approved for type 2 diabetes (Ozempic) and weight management (Wegovy).

15What this page cannot tell you

Whether semaglutide is appropriate for your individual clinical picture.
Whether a vial labelled ‘semaglutide’ from an online seller actually contains semaglutide.
How off-label use for cosmetic weight loss compares clinically to the licensed indications.
Whether you meet NICE TA875 NHS criteria — that needs a specialist assessment.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Long-term cardiovascular outcomes in patients without diabetes.
Optimal duration of weight-management therapy and management of post-discontinuation regain.
Specific safety data for adolescents and older adults.
Population-level effects on related conditions (cardiovascular, renal, cognitive).

19Safer alternatives / established care pathways

Licensed Wegovy or Mounjaro via NHS specialist service or GMC-registered private prescriber.
Structured weight-management programmes (Tier 2 / Tier 3 services).
Bariatric assessment for patients meeting NICE criteria.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Am I eligible for NHS GLP-1 access, or is private the appropriate route?
What dose-escalation plan are you proposing and why?
How will gastrointestinal side effects be managed?
What should I do if I plan to stop the medicine — both for side effects and for weight regain?
What should I check on the genuine packaging when I collect my prescription?
If I notice a side effect, do I report it via you, NHS 111, or the Yellow Card scheme?

Discovery & History

Semaglutide was developed by Novo Nordisk, building on decades of research into GLP-1 and its therapeutic potential. The company had previously developed liraglutide (Victoza/Saxenda), an earlier GLP-1 analogue, and sought to create a longer-acting compound. The key innovation was the modification of the GLP-1 molecule to resist degradation by dipeptidyl peptidase-4 (DPP-4) and to bind to albumin, dramatically extending its half-life. This was achieved through amino acid substitutions and the addition of a fatty acid side chain. Semaglutide received FDA approval for type 2 diabetes (as Ozempic) in 2017, followed by EMA approval. The once-weekly injectable formulation represented a significant advance in convenience over daily or twice-daily alternatives. In 2021, the FDA approved a higher dose of semaglutide (2.4 mg weekly) under the brand name Wegovy specifically for chronic weight management. This followed the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme, which demonstrated unprecedented weight loss results. An oral formulation (Rybelsus) was also developed using novel absorption-enhancing technology, becoming the first oral GLP-1 treatment for diabetes. Semaglutide has become one of the most commercially successful pharmaceutical products, with high demand creating supply challenges in some markets.

Mechanism of Action

Semaglutide exerts its effects through activation of GLP-1 receptors throughout the body: **Pancreatic Effects** Semaglutide stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner—meaning insulin is only released when blood glucose is elevated. This reduces the risk of hypoglycaemia. It also suppresses glucagon secretion from alpha cells, further improving glucose control. **Appetite Regulation** GLP-1 receptors in the brain, particularly in the hypothalamus and brainstem, mediate semaglutide's appetite-suppressing effects. Activation of these receptors promotes feelings of fullness (satiety) and reduces hunger, leading to decreased food intake. **Gastric Effects** Semaglutide slows gastric emptying, meaning food remains in the stomach longer. This contributes to increased satiety and more stable post-meal glucose levels. **Cardiovascular Effects** Clinical trials have demonstrated cardiovascular benefits, including reduced risk of major adverse cardiovascular events in high-risk patients. The mechanisms may include direct effects on the heart and blood vessels, as well as indirect benefits from improved metabolic parameters. **Extended Duration** The modified structure of semaglutide—including a fatty acid chain that binds to albumin—extends its half-life to approximately one week, allowing once-weekly dosing.

Researched Benefits

Based on preclinical and clinical research findings:

1
Significant weight loss averaging 15-17% of body weight in obesity trials
2
Improved glycaemic control in type 2 diabetes
3
Reduced HbA1c levels by 1-2 percentage points
4
Cardiovascular risk reduction in high-risk patients
5
Decreased appetite and food cravings
6
Improved blood pressure and lipid profiles
7
Potential benefits for non-alcoholic fatty liver disease
8
Reduced waist circumference and visceral fat

Claim vs Evidence

How popular claims about Semaglutide stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Causes substantial weight loss (~15% body weight)”	A	Yes	Low	Large human RCTs (STEP programme) show mean weight loss around 15% at 68 weeks for Wegovy 2.4 mg, with individual variation.
“Reduces cardiovascular events in eligible patients”	B	Yes	Low	Cardiovascular outcomes data exist; the magnitude and applicability depend on the specific population and indication.
“Available over-the-counter online — no prescription needed”	E	No	High	Semaglutide is a UK prescription-only medicine. Online sources selling it without a prescription operate outside UK law.
“Research-only semaglutide vials are equivalent to Wegovy”	E	No	High	Grey-market 'research' product is not verifiable as genuine pharma-grade semaglutide. Identity, purity, and dosing are unverified.
“No side effects — perfectly safe”	E	No	High	Common side effects are mostly gastrointestinal. Rarer serious risks exist. Always discuss with a prescriber.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	For obesity: 2.4 mg weekly (Wegovy); For diabetes: 0.5-1 mg weekly (Ozempic)
Frequency	Once weekly subcutaneous injection; oral (Rybelsus) taken daily
Duration	Long-term/ongoing treatment typically required to maintain benefits
Notes	Semaglutide is a prescription medication and should only be used under medical supervision. Dosage is typically escalated gradually to reduce gastrointestinal side effects. Treatment decisions should be made with a qualified healthcare provider.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection (once weekly)
Oral tablet (once daily - Rybelsus)

Half-Life	Stability
Approximately 7 days, enabling once-weekly administration	Pens should be stored refrigerated before first use; stable at room temperature for limited periods after

Safety Profile & Known Risks

Commonly Reported Side Effects

Nausea (especially during dose escalation)
Vomiting
Diarrhoea
Constipation
Abdominal pain
Decreased appetite
Fatigue

Rare Risks & Concerns

Pancreatitis (inflammation of the pancreas)
Gallbladder problems including gallstones
Thyroid tumours (seen in rodent studies; relevance to humans uncertain)
Hypoglycaemia (especially when combined with insulin or sulfonylureas)
Acute kidney injury (usually related to dehydration from GI effects)
Diabetic retinopathy complications (in patients with existing retinopathy)

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
History of pancreatitis
Pregnancy and breastfeeding
Severe gastrointestinal disease
Type 1 diabetes

UK & EU Regulatory Context

🇬🇧 United Kingdom

MHRA approved. Ozempic licensed for type 2 diabetes; Wegovy licensed for weight management.

🇪🇺 European Union

EMA approved for type 2 diabetes (Ozempic) and weight management (Wegovy).

Semaglutide is a fully approved prescription medication in the UK, EU, USA, and many other countries. It should only be obtained through legitimate medical channels and used under healthcare supervision.

Clinical Studies Summary

STEP 1: Semaglutide in Adults with Overweight or Obesity

Landmark trial showing 14.9% weight loss with semaglutide 2.4 mg vs 2.4% with placebo over 68 weeks in adults with obesity.

N Engl J Med. 2021View on PubMed

SUSTAIN-6: Cardiovascular Outcomes with Semaglutide

Demonstrated 26% reduction in major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.

N Engl J Med. 2016View on PubMed

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

Potent GLP-1 RAs, such as tirzepatide and semaglutide, demonstrate greater overall weight loss but are associated with a significant reduction in lean mass. None is related to this paper. CSM recused himself from handling this paper.

Metabolism. 2025View on PubMed

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.

In this systematic review and meta-analysis, discontinuing GLP-1RA treatment led to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those patients prescribed semaglutide/tirzepatide. The proportion of weight regained was proportional to the amount originally lost.

Obes Rev. 2025View on PubMed

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.

GLP-1RAs are efficacious in treating adults with type 2 diabetes. Compared with the placebo, tirzepatide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A1c and fasting plasma glucose concentrations. GLP-1RAs also significantly improved weight management for type 2 diabetes, with CagriSema performing the best for weight loss.

BMJ. 2024View on PubMed

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.

Diabetologia. 2024View on PubMed

Registered Trials & Regulatory Status

Registered trials

243

Currently recruiting

Furthest phase

Phase 4

Approved product

Yes

OZEMPIC, RYBELSUS

67 of 90 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

PHASE2

Status: Not Yet Recruiting · 240 participants · Ministry of Health, Saudi Arabia

Conditions: Type 1 Diabetes Mellitus

No results postedNCT07614412

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

PHASE1/PHASE2

Status: Not Yet Recruiting · 30 participants · Vanderbilt University Medical Center

Conditions: Duchenne Muscular Dystrophy (DMD)

No results postedNCT07642635

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

PHASE2

Status: Not Yet Recruiting · 40 participants · Kirby Institute

Conditions: Methamphetamine Use Disorder

No results postedNCT07509112

GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

PHASE4

Status: Not Yet Recruiting · 396 participants · Peking Union Medical College Hospital

Conditions: Hypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing

No results postedNCT07617155

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

PHASE3

Status: Not Yet Recruiting · 80 participants · Novo Nordisk A/S

Conditions: Diabetes Mellitus, Type 2

No results postedNCT07282613

Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

PHASE4

Status: Not Yet Recruiting · 240 participants · Alain Dagher

Conditions: Class I/II Obesity

No results postedNCT07592546

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

PHASE3

Status: Not Yet Recruiting · 956 participants · The United Bio-Technology (Hengqin) Co., Ltd.

Conditions: Type 2 Diabetes

No results postedNCT07653477

Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

PHASE1/PHASE2

Status: Not Yet Recruiting · 24 participants · Mapi Pharma Ltd.

Conditions: Diabete Type 2

No results postedNCT07563699

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

PHASE2

Status: Not Yet Recruiting · 164 participants · Biophytis

Conditions: Muscle Wasting, Obesity & Overweight, Obesity

No results postedNCT07411378

Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant

PHASE1

Status: Not Yet Recruiting · 20 participants · Vivani Medical, Inc

Conditions: Obesity & Overweight

No results postedNCT07430059

Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

PHASE2

Status: Not Yet Recruiting · 100 participants · Population Health Research Institute

Conditions: Ischemic Stroke

No results postedNCT07511543

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

PHASE1

Status: Recruiting · 62 participants · Terrestrial Bio, Inc.

Conditions: Overweight and/or Obesity

No results postedNCT07673900

Adverse event reports (FDA FAERS)

nausea943
vomiting835
diarrhoea589
off label use426
fatigue396
dyspnoea382
weight decreased379
drug ineffective374
dizziness328
headache305

FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Semaglutide?

Source research-grade Semaglutide from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Semaglutide

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Am I eligible for NHS GLP-1 access, or is private the appropriate route?
What dose-escalation plan are you proposing and why?
How will gastrointestinal side effects be managed?
What should I do if I plan to stop the medicine — both for side effects and for weight regain?
What should I check on the genuine packaging when I collect my prescription?
If I notice a side effect, do I report it via you, NHS 111, or the Yellow Card scheme?

Quick Facts

Overview

01Evidence snapshot

02Human evidence grade

03Preclinical evidence grade

04Regulatory status

05Approved medical uses

06Unapproved / promotional claims

07Common internet claims

08Claim vs evidence

09Safety uncertainty score

10Known adverse signals

11Drug-interaction uncertainty

12Anti-doping status

13UK legal position

14EU legal position

15What this page cannot tell you

16Last reviewed

17Citation quality score

18Research gaps

19Safer alternatives / established care pathways

20Doctor discussion prompts

Questions to ask a qualified clinician

Discovery & History

Mechanism of Action

Researched Benefits

Claim vs Evidence

Theoretical Dosing & Protocols

Administration Routes

Safety Profile & Known Risks

Commonly Reported Side Effects

Rare Risks & Concerns

Contraindications

UK & EU Regulatory Context

🇬🇧 United Kingdom

🇪🇺 European Union

Clinical Studies Summary

STEP 1: Semaglutide in Adults with Overweight or Obesity

SUSTAIN-6: Cardiovascular Outcomes with Semaglutide

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

Registered Trials & Regulatory Status

SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.

Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.

Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant

Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

Adverse event reports (FDA FAERS)

Looking for Semaglutide?

Frequently Asked Questions

What is semaglutide used for?

How much weight can you lose on semaglutide?

Is semaglutide safe?

How long do you need to take semaglutide?

What is the difference between Ozempic and Wegovy?

Questions to ask a qualified clinician about Semaglutide

UK regulatory & safety context

Semaglutide and UK law

Fake weight-loss pens

Related Research Guides

Peptides for Fat Loss

Related Peptides

Liraglutide

Tesofensine

GLP-1

Tirzepatide

Explore More Peptides